Genetic testing in prostate cancer management: Considerations informing primary care. (24th February 2022)

• Record Type: Journal Article
• Authors: Giri, Veda N.; Morgan, Todd M.; Morris, David S.; Berchuck, Jacob E.; Hyatt, Colette; Taplin, Mary‐Ellen
• Is Part Of: CA. Volume 72:Number 4(2022)
• Page Start: 360
• Page End: 371
• Publication Date: 2022-02-24
• Subjects: genetic counseling -- genetic testing -- primary care -- prostate cancer -- targeted therapy; Cancer -- Periodicals; Neoplasms -- Periodicals; Neoplasms; 616.99405
• DOI: 10.3322/caac.21720
• Languages: English
• ISSNs: 0007-9235

Abstract

Abstract: Inherited genetic mutations can significantly increase the risk for prostate cancer (PC), may be associated with aggressive disease and poorer outcomes, and can have hereditary cancer implications for men and their families. Germline genetic testing (hereditary cancer genetic testing) is now strongly recommended for patients with advanced/metastatic PC, particularly given the impact on targeted therapy selection or clinical trial options, with expanded National Comprehensive Cancer Network guidelines and endorsement from multiple professional societies. Furthermore, National Comprehensive Cancer Network guidelines recommend genetic testing for men with PC across the stage and risk spectrum and for unaffected men at high risk for PC based on family history to identify hereditary cancer risk. Primary care is a critical field in which providers evaluate men at an elevated risk for PC, men living with PC, and PC survivors for whom germline testing may be indicated. Therefore, there is a critical need to engage and educate primary care providers regarding the role of genetic testing and the impact of results on PC screening, treatment, and cascade testing for family members of affected men. This review highlights key aspects of genetic testing in PC, the role of clinicians, with a focus on primary care, the importance of obtaining a comprehensive family history, current germline testing guidelines, and the impact on precision PC care. With emerging evidence and guidelines, clinical pathways are needed to facilitate integrated genetic education, testing, and counseling services in appropriately selected patients. There is also a need for providers to understand the field of genetic counseling and how best to collaborate to enhance multidisciplinary patient care.